Inhibition of JAK3 has been explored as an alternative therapy to cyclosporine in transplant rejection and in treatment of rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn’s disease, and dry eye syndrome [51]. This evidence concerns the gene JAK3 and psoriasis.